- Home
- PASG vs GTBP Comparison
PASG vs GTBP Comparison
Compare PASG & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | GTBP |
|---|---|---|
| Founded | 2017 | 1965 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 17.7M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PASG | GTBP |
|---|---|---|
| Price | $4.70 | $0.49 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 96.3K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $0.26 |
| 52 Week High | $20.00 | $2.31 |
Technical Indicators
Market Signals| Indicator | PASG | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 54.84 |
| Support Level | $3.94 | $0.39 |
| Resistance Level | $6.01 | $0.57 |
| Average True Range (ATR) | 0.52 | 0.05 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 47.84 | 47.40 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.